share_log

MorphoSys' Monjuvi Shows Long-Term Durable Response In Blood Cancer Settings

MorphoSys' Monjuvi Shows Long-Term Durable Response In Blood Cancer Settings

Morphosys的Monjuvi在血癌治療中顯示出長期持久的反應
Benzinga Real-time News ·  2022/09/29 09:22
  • MorphoSys AG (NASDAQ:MOR) announced data from the ongoing L-MIND study showing that Monjuvi (tafasitamab-cxix) regime provided long-term efficacy in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated for at least two years, including six patients on treatment for five years or more.
  • The regime includes Monjuvi plus lenalidomide followed by Monjuvi monotherapy.
  • Additionally, the frequency of adverse events declined after patients transitioned from combination therapy to monotherapy.
  • A complete response was observed in 23 of the 27 patients who had undergone treatment, including four who were refractory to their primary therapy. A partial response was seen in four patients, two of whom were still on treatment at the data cutoff.
  • Most adverse events were mild or moderate during combination and monotherapy treatment. During monotherapy, patients experienced a lower frequency of all-grade and grade 3 or higher adverse events.
  • The most common adverse events with combination therapy were neutropenia and diarrhea, which declined after patients switched to monotherapy. They remained the most common adverse events in the first two years of monotherapy.
  • Tafasitamab is co-marketed by Incyte Corporation (NASDAQ:INCY).
  • Price Action: MOR shares are up 2.19% at $5.61 during the premarket session on the last check Thursday.
  • Morphosys公司納斯達克股票代碼：MOR)公佈的正在進行的L-Mind研究數據顯示，孟居維(他法他單抗-cxix)方案對治療至少兩年的復發或難治性(R/R)瀰漫性大B細胞淋巴瘤(DLBCL)具有長期療效，其中包括6名治療5年或更長時間的患者。
  • 該方案包括孟加拉度胺加來那度胺，然後是孟朱維單一療法。
  • 此外，在患者從聯合治療過渡到單一治療後，不良事件的頻率下降。
  • 在接受治療的27名患者中，有23人觀察到完全緩解，其中4人對最初的治療無效。四名患者出現部分緩解，其中兩人在數據截止時仍在接受治療。
  • 在聯合治療和單一治療期間，大多數不良事件都是輕微或中度的。在單一治療期間，患者經歷所有級別和3級或更高級別不良事件的頻率較低。
  • 聯合治療最常見的不良反應是中性粒細胞減少和腹瀉，在患者轉向單一治療後，這些不良反應有所下降。在單一療法的頭兩年，它們仍然是最常見的不良事件。
  • Tafasitamab由以下公司聯合營銷Incell公司(納斯達克：Incy)。
  • 價格行動：在週四最後一次檢查的盤前交易中，MOR股價上漲2.19%，至5.61美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論